Search

Displaying results 1221 - 1230 of 4539 in total
  1. Drug

    Lonidamine

    go.drugbank.com/drugs/DB06266
    Investigational

    Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK). … In such way LND could impair energy-requiring processes, as recovery from potentially lethal damage, induced by radiation treatment and by some cytotoxic drugs.

  2. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. … treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by

  3. Drug

    Ammonia

    go.drugbank.com/drugs/DB11118
    ApprovedInvestigational

    It is present in normally present in all tissues constituting a metabolic pool, where it is mostly taken up by glutamic acid and take part in transamination and other reactions, including the synthesis … of protein by the Krebs-Hanseleit cycle in the liver [L2033].

  4. Drug

    Cefaclor

    go.drugbank.com/drugs/DB00833
    ApprovedInvestigational

    Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.

  5. Drug

    Edotreotide gallium Ga-68

    go.drugbank.com/drugs/DB15494
    Approved

    [A185852] Dotatate gallium Ga-68 has lower tumor uptake but this data is highly variable between patients.[A185852] Edotreotide gallium Ga-68 was granted FDA approval on 21 August 2019.[L8597] … [L8603] Edotreotide gallium Ga-68 is indicated for localizing somatostatin receptor positive neuroendocrine tumors by positron emission tomography.

  6. Drug

    Gonadorelin

    go.drugbank.com/drugs/DB00644
    ApprovedInvestigationalVet approved

    Gonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormon...

  7. Drug

    Uprifosbuvir

    go.drugbank.com/drugs/DB15206
    Investigational

    Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis … C Genotype (GT)1 and GT2 Infection (MK-3682-011)).

  8. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    [L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide.[L41404] Eliglustat is mainly metabolized by CYP2D6. … [L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.

  9. Drug

    Dextran

    go.drugbank.com/drugs/DB09255
    ApprovedInvestigationalVet approved

    It is administered by intravenous infusion. Dextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons. … The main chain of glucose has short branches at frequent intervals which are probably joined by 1:3 and 1:4 glucoside links. The chains can be composed of about 200,000 glucose units.

    Mixtures: SK Advanced Relief Eye Drops
  10. Drug

    Copper histidinate

    go.drugbank.com/drugs/DB32041
    Approved

    It was approved by the US FDA in January 2026 for the treatment of pediatric patients with Menkes disease.[L54993,L54998] … Menkes disease is a rare, X-linked recessive disorder caused by pathogenic variants in the ATP7A gene, which encodes a copper transport protein essential for absorbing dietary copper and transporting it